Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Neuralstem is seeking permission to evaluate efficacy in its phase 1 safety trial, as well as to increase the dosage and number of trial participants
Posted on Wednesday, May 16, 2012 - 04:39, By: Amy Madsen
The biotherapeutics company Neuralstem is seeking to amend the design of its ongoing phase 1 stem cell trial in amyotrophic lateral sclerosis (ALS) to include evaluations of efficacy (how well the therapy works).
Although the phase 1 trial isn’t currently designed to evaluate efficacy, early...